Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2006 1
2007 1
2011 1
2015 2
2016 1
2017 2
2019 1
2020 2
2021 1
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K, Varas L, Deronic A, Nyesiga B, Sundstedt A, Ljung L, Sakellariou C, Werchau D, Thagesson M, Gomez Jimenez D, Greiff L, Celander M, Smedenfors K, Rosén A, Bölükbas D, Carlsson F, Levin M, Säll A, von Schantz L, Lindstedt M, Ellmark P. Hägerbrand K, et al. Among authors: varas l. J Immunother Cancer. 2022 Nov;10(11):e005018. doi: 10.1136/jitc-2022-005018. J Immunother Cancer. 2022. PMID: 36323431 Free PMC article.
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Nelson MH, Fritzell S, Miller R, Werchau D, Van Citters D, Nilsson A, Misher L, Ljung L, Bader R, Deronic A, Chunyk AG, Schultz L, Varas LA, Rose N, Håkansson M, Gross J, Furebring C, Pavlik P, Sundstedt A, Veitonmäki N, Ramos HJ, Säll A, Dahlman A, Bienvenue D, von Schantz L, McMahan CJ, Askmyr M, Hernandez-Hoyos G, Ellmark P. Nelson MH, et al. Among authors: varas la. Mol Cancer Ther. 2023 Jan 3;22(1):89-101. doi: 10.1158/1535-7163.MCT-22-0395. Mol Cancer Ther. 2023. PMID: 36343381 Free PMC article.
Inequality of opportunity in health: evidence from Chile.
Gallardo K, Varas L, Gallardo M. Gallardo K, et al. Among authors: varas l. Rev Saude Publica. 2017 Dec 4;51:110. doi: 10.11606/S1518-8787.2017051007034. Rev Saude Publica. 2017. PMID: 29211206 Free PMC article.
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
Enell Smith K, Fritzell S, Nilsson A, Barchan K, Rosén A, Schultz L, Varas L, Säll A, Rose N, Håkansson M, von Schantz L, Ellmark P. Enell Smith K, et al. Among authors: varas l. Cancer Immunol Immunother. 2023 Dec;72(12):4145-4159. doi: 10.1007/s00262-023-03548-7. Epub 2023 Oct 5. Cancer Immunol Immunother. 2023. PMID: 37796298 Free PMC article.
LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs.
Granadillo M, Batte A, Blanco A, Alfonso AB, Suárez J, Merino N, Carballo R, González BO, Prieto YC, Varas L, Soler D, Limonta M, Miyares M, Aldana L, Torrens I. Granadillo M, et al. Among authors: varas l. Clin Exp Metastasis. 2017 Apr;34(3-4):241-249. doi: 10.1007/s10585-017-9846-x. Epub 2017 Apr 17. Clin Exp Metastasis. 2017. PMID: 28417212
18 results